108 related articles for article (PubMed ID: 21635208)
1. Exploring QSARs for inhibitory effect of a set of heterocyclic thrombin inhibitors by multilinear regression refined by artificial neural network and molecular docking simulations.
Ramírez-Galicia G; Garduño-Juárez R; Correa-Basurto J; Deeb O
J Enzyme Inhib Med Chem; 2012 Apr; 27(2):174-86. PubMed ID: 21635208
[TBL] [Abstract][Full Text] [Related]
2. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
3. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation.
Votano JR; Parham M; Hall LM; Hall LH; Kier LB; Oloff S; Tropsha A
J Med Chem; 2006 Nov; 49(24):7169-81. PubMed ID: 17125269
[TBL] [Abstract][Full Text] [Related]
4. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
5. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
6. Exploring the ligand recognition properties of the human vasopressin V1a receptor using QSAR and molecular modeling studies.
Contreras-Romo MC; Martínez-Archundia M; Deeb O; Slusarz MJ; Ramírez-Salinas G; Garduño-Juárez R; Quintanar-Stephano A; Ramírez-Galicia G; Correa-Basurto J
Chem Biol Drug Des; 2014 Feb; 83(2):207-23. PubMed ID: 24010681
[TBL] [Abstract][Full Text] [Related]
7. Modeling the antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides using different chemometrics methods.
Garkani-Nejad Z; Ahmadi-Roudi B
Eur J Med Chem; 2010 Feb; 45(2):719-26. PubMed ID: 19959260
[TBL] [Abstract][Full Text] [Related]
8. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling studies, synthesis and biological evaluation of dabigatran analogues as thrombin inhibitors.
Dong MH; Chen HF; Ren YJ; Shao FM
Bioorg Med Chem; 2016 Jan; 24(2):73-84. PubMed ID: 26690913
[TBL] [Abstract][Full Text] [Related]
10. Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus.
Patra JC; Singh O
J Comput Chem; 2009 Nov; 30(15):2494-508. PubMed ID: 19373836
[TBL] [Abstract][Full Text] [Related]
11. A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors.
Hu L; Chen G; Chau RM
J Mol Graph Model; 2006 Jan; 24(4):244-53. PubMed ID: 16226911
[TBL] [Abstract][Full Text] [Related]
12. Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin.
Greenidge PA; Mérette SA; Beck R; Dodson G; Goodwin CA; Scully MF; Spencer J; Weiser J; Deadman JJ
J Med Chem; 2003 Apr; 46(8):1293-305. PubMed ID: 12672230
[TBL] [Abstract][Full Text] [Related]
13. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques.
Wei HY; Tsai KC; Lin TH
J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
15. Quantitative structure activity relationship studies of aryl heterocycle-based thrombin inhibitors.
Deswal S; Roy N
Eur J Med Chem; 2006 Nov; 41(11):1339-46. PubMed ID: 16884829
[TBL] [Abstract][Full Text] [Related]
16. Fuzzy tricentric pharmacophore fingerprints. 2. Application of topological fuzzy pharmacophore triplets in quantitative structure-activity relationships.
Bonachéra F; Horvath D
J Chem Inf Model; 2008 Feb; 48(2):409-25. PubMed ID: 18254617
[TBL] [Abstract][Full Text] [Related]
17. QSAR for anti-HIV activity of HEPT derivatives.
Bazoui H; Zahouily M; Boulajaaj S; Sebti S; Zakarya D
SAR QSAR Environ Res; 2002 Oct; 13(6):567-77. PubMed ID: 12479372
[TBL] [Abstract][Full Text] [Related]
18. QSAR modeling of the inhibition of glycogen synthase kinase-3.
Katritzky AR; Pacureanu LM; Dobchev DA; Fara DC; Duchowicz PR; Karelson M
Bioorg Med Chem; 2006 Jul; 14(14):4987-5002. PubMed ID: 16650999
[TBL] [Abstract][Full Text] [Related]
19. Molecule kernels: a descriptor- and alignment-free quantitative structure-activity relationship approach.
Mohr JA; Jain BJ; Obermayer K
J Chem Inf Model; 2008 Sep; 48(9):1868-81. PubMed ID: 18767832
[TBL] [Abstract][Full Text] [Related]
20. Modelling of retention of pesticides in reversed-phase high-performance liquid chromatography: quantitative structure-retention relationships based on solute quantum-chemical descriptors and experimental (solvatochromic and spin-probe) mobile phase descriptors.
D'Archivio AA; Ruggieri F; Mazzeo P; Tettamanti E
Anal Chim Acta; 2007 Jun; 593(2):140-51. PubMed ID: 17543600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
